Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, announced today that its board of directors has granted 1,297,000 incentive stock options to directors, officers, employees, and consultants under its equity compensation plan. Each option is exercisable to acquire one common share at $1.63 per share for five years from the grant date, subject to vesting provisions. Concurrently, the company canceled 2,200,000 stock options previously granted to a director on July 19, 2024, which had an exercise price of $1.10 per share and were set to expire in 2029. The director did not receive new options in the current grant.
These actions underscore Helix’s ongoing efforts to align incentives with its strategic goals as it advances its oncology pipeline. The company is focused on developing therapies for hard-to-treat cancers, led by its Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate targeting CEACAM6-expressing tumors. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and serves as the foundation for next-generation bi-specific antibody-drug conjugates (ADCs) in discovery. Additionally, Helix is advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability comparable to IV administration.
The cancellation of the director’s options, which represented a significant portion of previously granted incentives, may indicate a strategic realignment of compensation or a response to changing circumstances. The grant of new options with a higher exercise price ($1.63 vs. $1.10) reflects the company’s current share price and may serve to retain and motivate key personnel as Helix progresses toward key milestones. According to the company’s forward-looking statements, these decisions are based on assumptions about the benefits of the equity compensation plan and the company’s future performance. However, risks remain, including those outlined in Helix’s periodic filings on SEDAR+ at www.sedarplus.ca.
Helix BioPharma is listed on the TSX, OTC PINK, and Frankfurt Stock Exchange. For more information, visit https://www.helixbiopharma.com/. The company’s pipeline aims to make today’s hard-to-treat cancers vincible, with a focus on near-term solutions. The stock option adjustments are a routine part of corporate governance but gain significance given the company’s clinical-stage status and the need to align management interests with shareholder value. As Helix continues to develop its candidates, the compensation structure will be closely watched by investors for signs of confidence and commitment from leadership.
